🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,041 results for “Advanced” Clear

  1. Cemiplimab

    Regeneron UK Limited

    Locally Advanced Head and Neck Squamous Cell Carcinoma

    phase 1 small molecule active

    1 trial

  2. Ceralasertib

    AstraZeneca

    Advanced Solid Malignancies

    phase 1 small molecule completed

    1 trial

  3. Ceralasertib, IMFINZI 50 mg/mL concentrate for solution for infusion, INFLIXIMAB, MYCOPHENOLATE MOFETIL, AZD4773, IMJUDO 20 mg/ml concentrate for solution for infusion.

    AstraZeneca AB

    • Non-small cell lung cancer (Stage III, unresectable) • Small cell lung cancer (Limited stage) • Hepatocellular carcinoma (Unresectable) • Advanced or Metastatic non-small cell lung cancer

    phase 1 small molecule active

    1 trial

  4. Cisplatin

    United Therapeutics Europe Ltd

    Advanced Cholangiocarcinoma

    phase 1 small molecule terminated

    1 trial

  5. Cisplatin

    AstraZeneca

    Inoperable Locally Advanced or Metastatic Biliary Tract Cancer

    phase 1 small molecule terminated

    1 trial

  6. Clinical study to evaluate the safety of investigational medicinal product called AD-O51.4 in patients with advanced malignancies

    Lacuna Pharma Pty Ltd

    Patients suffering from cancer without further treatment options.

    phase 1 other active

    1 trial

  7. Clinical trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer

    BioNTech SE

    Advanced non-small cell lung cancer

    phase 1 other active

    1 trial

  8. Cobimetinib

    Cardiff Oncology

    Locally Advanced Pancreatic Ductal Adenocarcinoma

    phase 1 small molecule active

    1 trial

  9. Comparison between ABP 234 and Keytruda® (Pembrolizumab)

    Amgen

    Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  10. Concurrent chemotherapy

    Sun Yat-sen University

    Locally Advanced Lung Carcinoma

    phase 1 small molecule completed

    1 trial

  11. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Locally Advanced Melanoma

    phase 1 small molecule active

    1 trial

  12. DABRAFENIB MESYLATE, TMT212, CANAKINUMAB, DKY709, LXH254, TRAMETINIB DIMETHYL SULFOXIDE, NIR178, MCS110, LXH254, INC280, TMT212, PDR001, NIR178, PDR001, NIZ985, TRAMETINIB DIMETHYL SULFOXIDE, LAG525, NIR178, LXH254, DABRAFENIB MESYLATE

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 1 small molecule active

    1 trial

  13. DAREON™-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendocrine cancers

    Boehringer Ingelheim

    Extra-pulmonary neuroendocrine carcinoma (epNEC), Neuroendocrine carcinoma (NEC) with unknown primary site, pulmonary Large cell neuroendocrine carcinoma (LCNEC)

    phase 1 other active

    1 trial

  14. DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small cell lung cancer

    Boehringer Ingelheim

    Extensive-stage small cell lung carcinoma (ES-SCLC)

    phase 1 other active

    1 trial

  15. DEXTROMETHORPHANE ELERTE 1,5 mg/ml, sirop, AZD3470, AZD3470, Midazolam-ratiopharm® 2 mg/ml orale Lösung

    AstraZeneca AB

    Advanced/metastatic solid tumors that are MTAP deficient.

    phase 1 small molecule active

    1 trial

  16. Debio 0123, Debio 0123, Debio 0123, Debio 2513, Debio 0123, Debio 2513, Debio 0123, Debio 0123

    Alphapharm Pty Ltd

    Advanced solid tumors with CCNE1 amplification or deleterious mutations in FBXW7 or other proprietary gene

    phase 1 small molecule active

    1 trial

  17. Demcizumab

    Mereo BioPharma Group plc

    Locally Advanced or Metastatic Solid Tumors

    phase 1 small molecule completed

    1 trial

  18. Drug: BG-T187

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  19. Dual-Wavelength Quantitative Fluorescence Endoscopy for Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer: A Phase I Multicenter Feasibility and Safety Study

    Disc Medicine

    Esophageal cancer

    phase 1 other active

    1 trial

  20. EBC-129

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumours

    phase 1 small molecule active

    1 trial

  21. ENMD-2076

    CASI Pharmaceuticals

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  22. ETC-159

    BRIGHT MINDS BIOSCIENCES INC.

    With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

    phase 1 small molecule active

    1 trial

  23. EVM16

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced or Recurrent Solid Tumors

    phase 1 mab active

    1 trial

  24. Elimusertib (BAY1895344)

    Bayer HealthCare AG

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources